[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-445676-105":59,"doc-detail-445676-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","s12-oral-presentations-op24-cost-effectiveness-of-monitoring-ocular-hypertension-based-on-a-risk-prediction-tool","S12 Oral Presentations - OP24 Cost Effectiveness Of Monitoring Ocular Hypertension Based On A Risk Prediction Tool","","Glaucoma is a leading cause of blindness, and ocular hypertension (OHT) is a modifiable risk factor through regular monitoring and timely treatment. Rising OHT prevalence from population aging strains the UK healthcare system, motivating assessment of a risk prediction (RP) tool to guide treatment decisions. A discrete-event simulation compared RP-guided secondary-care pathways with standard care. Using electronic medical record-derived patient risk characteristics (n=5,740), the RP strategy produced higher QALYs at higher costs and remained cost effective (ICER GBP11,522) with a 96% probability below GBP20,000 per QALY.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/s12-oral-presentations-op24-cost-effectiveness-of-monitoring-ocular-hypertension-based-on-a-risk-prediction-tool/445676/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/s12-oral-presentations-op24-cost-effectiveness-of-monitoring-ocular-hypertension-based-on-a-risk-prediction-tool/445676.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem is addressed in OP24?","Question",{"text":112,"@type":113},"OP24 evaluates whether using a validated risk prediction tool to guide monitoring and treatment for ocular hypertension can be cost effective while addressing rising patient numbers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the economic evaluation performed?",{"text":117,"@type":113},"A discrete event simulation model compared an RP-guided care pathway in secondary care versus standard care, using individual patient sampling and risk characteristics derived from electronic medical records.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings on cost effectiveness?",{"text":121,"@type":113},"The RP strategy yielded higher quality-adjusted life years than standard care and was cost effective in the base case, with an ICER of GBP11,522 and a 96% probability of being cost effective under a GBP20,000 per QALY threshold.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},445676,1790814676,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","S12 Oral Presentations  \nOP24 Cost Effectiveness Of Monitoring Ocular Hypertension Based On A Risk Prediction Tool  \nHangjian Wu, Gus Gazzard, Anthony King, James Morgan,  \nDavid Wright, David Crabb, Yemisi Takwoingi, Augusto Azuara-Blanco, Verity Watson and Rodolfo Hernández ([r.a.hernandez@abdn.ac.uk](r.a.hernandez@abdn.ac.uk))  \nIntroduction: Glaucoma is a leading cause ofblindness. Ocular hypertension(OHT)is a key risk factor modifiable by regular monitoring and treatment. Population aging leads to rapid rise of OHT patients, and thus overburdens the UK healthcare system, but innovative technology may provide a solution. We assessed the cost effectiveness of making treatment decisions based on a validated risk prediction (RP) tool. Methods: A discrete event simulation model was constructed to compare the cost effectiveness of an alternative care pathway in which the treatment decision was guided by a validated RP tool in secondary care against decision-making based on standard care (SC) . Individual patient sampling was used. Patients diagnosed with OHT and with an intraocular pressure of at least 24 mmHg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. These characteristics were retrieved from electronic medical records (n=5,740) . Different stages of glaucoma were modeled following conversion to glaucoma. Results: Almost all (99%) patients were treated using the RP strategy, and less than half (47%) of the patients were treated using the SC strategy. The RP strategy produced higher cost but also higher qualityadjusted life years (QALYs) than the SC strategy. The RP strategy was cost effective compared with the SC strategy in the base case analysis, with an incremental cost-effectiveness ratio value of GBP11,522 (USD15,843). The RP strategy had a 96 percent probability of being cost effective under a GBP20,000 (USD27,500) per QALY threshold. Conclusions: The use of an RP tool for the management of patients with OHT is likely to be cost effective. However, the generalizability of the result might be limited due to the high risk nature of this cohort and the specific RP threshold used in the study.  \nOP25 Teleradiology PublicPrivate Partnership Models: Informing Health Technology Assessment Findings In India  \nAnupama Sharma ([asharma@msh.org](asharma@msh.org)), Ranjan Choudhury and Anjaney Shahi  \nIntroduction: In India, the Free Diagnostic Service Initiative leverages teleradiology and technology to address the shortage of skilled radiologists, improving healthcare access. X-ray films are digitized  \nfor remote reporting, enhancing equitable healthcare delivery. The study explored teleradiology public-private partnership (PPP) models, emphasizing their synergy with artificial intelligence (AI) as a scalable solution to strengthen public health services in low-and middle-income countries.  \nMethods: The study prospectively analyzed telereporting services under PPP models across Indian states and union territories and reviewed literature from January to July 2023 . Data from Program Implementation Plans and Records of Proceedings were examined. The study assessed resources, expertise, and accountability using the World Health Organization’s Public-Private Mix Framework, which focused on Enabling Environment, Service Delivery, and Monitoring & Evaluation. It highlighted infrastructure challenges, skilled human resource needs, and impacts on access, equity, regulation, incentives, innovation, and uptake in radiology systems, emphasizing resourceintensive digitization (Digital Imaging and Communications in Medicine; Picture Archiving and Communication System). The findings provide insights into the distribution of responsibilities between public and private entities for effective healthcare delivery.  \nResults: Teleradiology PPP services in India, implemented in 14 out of 36 states, were categorized into three models: outsourcing X-ray and telereporting, out","cbCaiqrabnilgEbm","https://ap.wps.com/l/cbCaiqrabnilgEbm","pdf",32306,"English","# S12 Oral Presentations\n## OP24 Cost Effectiveness Of Monitoring Ocular Hypertension Based On A Risk Prediction Tool\n## Introduction\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What clinical problem is addressed in OP24?\",\"answer\":\"OP24 evaluates whether using a validated risk prediction tool to guide monitoring and treatment for ocular hypertension can be cost effective while addressing rising patient numbers.\"},{\"question\":\"How was the economic evaluation performed?\",\"answer\":\"A discrete event simulation model compared an RP-guided care pathway in secondary care versus standard care, using individual patient sampling and risk characteristics derived from electronic medical records.\"},{\"question\":\"What were the key findings on cost effectiveness?\",\"answer\":\"The RP strategy yielded higher quality-adjusted life years than standard care and was cost effective in the base case, with an ICER of GBP11,522 and a 96% probability of being cost effective under a GBP20,000 per QALY threshold.\"}]","S12 Oral Presentations - OP24 Cost Effectiveness Of Monitoring Ocular Hypertension Based On A Risk Prediction Tool | PDF",1790712552]